All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F23%3A00078535" target="_blank" >RIV/65269705:_____/23:00078535 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216224:14110/23:00133687

  • Result on the web

    <a href="https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2023.28.47.2300186" target="_blank" >https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2023.28.47.2300186</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.2807/1560-7917.ES.2023.28.47.2300186" target="_blank" >10.2807/1560-7917.ES.2023.28.47.2300186</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021

  • Original language description

    IntroductionTwo large multicentre European hospital networks have estimated vaccine effectiveness (VE) against COVID-19 since 2021.AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in hospitalised severe acute respiratory illness (SARI) patients &gt;= 20 years, combining data from these networks during Alpha (March-June)- and Delta (June-December)-dominant periods, 2021.MethodsForty-six participating hospitals across 14 countries follow a similar generic protocol using the test-negative case-control design. We defined complete primary series vaccination (PSV) as two doses of a two-dose or one of a single-dose vaccine &gt;= 14 days before onset.ResultsWe included 1,087 cases (538 controls) and 1,669 cases (1,442 controls) in the Alpha- and Delta-dominant periods, respectively. During the Alpha period, VE against hospitalisation with SARS-CoV2 for complete Comirnaty PSV was 85% (95% CI: 69-92) overall and 75% (95% CI: 42-90) in those aged &gt;= 80 years. During the Delta period, among SARI patients &gt;= 20 years with symptom onset &gt;= 150 days from last PSV dose, VE for complete Comirnaty PSV was 54% (95% CI: 18-74). Among those receiving Comirnaty PSV and mRNA booster (any product) &gt;= 150 days after last PSV dose, VE was 91% (95% CI: 57-98). In time-since-vaccination analysis, complete all-product PSV VE was &gt; 90% in those with their last dose &lt; 90 days before onset; &gt;= 70% in those 90-179 days before onset.ConclusionsOur results from this EU multi-country hospital setting showed that VE for complete PSV alone was higher in the Alpha- than the Delta-dominant period, and addition of a first booster dose during the latter period increased VE to over 90%.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30303 - Infectious Diseases

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2023

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Eurosurveillance

  • ISSN

    1025-496X

  • e-ISSN

    1560-7917

  • Volume of the periodical

    28

  • Issue of the periodical within the volume

    47

  • Country of publishing house

    SE - SWEDEN

  • Number of pages

    16

  • Pages from-to

    2300186

  • UT code for WoS article

    001117609400005

  • EID of the result in the Scopus database

    2-s2.0-85177867806